A novel retinoic acid chalcone reverses epithelial-mesenchymal transition in prostate cancer cells

  • Jian Zhong Department of Urology, The First Hospital Affiliated to Soochow University, Suzhou, Jiangsu 215 006, China
  • Jian-Quan Hou Department of Urology, The First Hospital Affiliated to Soochow University, Suzhou, Jiangsu 215 006, China
Keywords: Prostate cancer, mesenchymal marker, invasiveness, transcription factor, cell motility


The present study was performed to investigate the effect of retinoic acid fluoro chalcone (RAFC) on lipopolysaccharide (LPS) induced epithelial-mesenchymal transition (EMT) in PC3 and CWR22rv1 prostate cell lines. Lipo-polysaccharide (LPS) was used to induce epithelial-mesenchymal transition in prostate carcinoma cell lines. The results revealed that treatment of PC3 and CWR22rv1 cells with LPS resulted in significant changes in the morphological features of the EMT. The mesenchymal marker, vimentin expression was significantly increased whereas the expression level of E?cadherin was markedly decreased after the treatment. We also observed increased cell motility and higher level of transcription factor glioma?associated oncogene homolog 1 (Gli1) expression on LPS treatment. Treatment of prostate cells with RAFC reversed the morphological changes induced by LPS in prostate cells. RAFC also reduced the expression of EMT markers induced by LPS and suppressed the Gli1 expression. The resultant effect of these changes was the suppression of motility and invasiveness of the prostrate cells. Thus, RAFC exhibited anti?invasive effect on prostrate cells by inhibition of the EMT process via Hedgehog signaling pathway.


Download data is not yet available.
558 Read


Bhavsar T, McCue P, Birbe R. Molecular diagnosis of prostate cancer: Are we up to age? Semin Oncol. 2013; 40: 259?75.

Chung KD. Jeong Young-Il, Chung CW, Kim DH, Kang DH. Anti-tumor activity of all-trans retinoic acid-incorporated glycol chitosan nanoparticles against HuCC-T1 human cholangiocarcinoma cells. Int J Pharmaceut. 2012; 422: 454-61.

Clyne M. Prostate cancer: androgen deprivation causes EMT in the prostate. Nat Rev Urol. 2012; 9: 4.

Crocetti E, Trama A, Stiller C, Caldarella A, et al. Epide­miology of glial and non-glial brain tumors in Europe. Eur J Cancer. 2012; 48: 1532-42.

De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013; 13: 97?110.

Defer GL, Adle-Biassette H, Ricolfi F, Martin L, Authier FJ, Chomienne C, Degos L, Degos J. All-trans retinoic acid in relapsing malignant gliomas: Clinical and radiological stabilization associated with the appearance of intratumoral calcifications. J Neurooncol. 1997; 34: 169-77.

Evdokimova V, Tognon CE, Sorensen PH. On translational regulation and EMT. Semin Cancer Biol. 2012; 22: 437?45.

Franco?Chuaire ML, Magda Carolina CS, Chuaire?Noack L. Epithelial?mesenchymal transition (EMT): Principles and clinical impact in cancer therapy. Invest Clin. 2013; 54: 186?205.

Fryer RA, Galustian C, Dalgleish AG, Dalgelish AG. Recent advances and developments in treatment strategies against pancreatic cancer. Curr Clin Pharmacol. 2009; 4: 102?12.

Hance MW, Dole K, Gopal U, et al. Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer. J Biol Chem. 2012; 287: 37732?44.

Huang EJ, Ye YC, Chen SR, Chai JR, Lu, JX, Zhoa L, Gu LJ, Wang ZY. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-72.

Jeong YI, Kim SH, Jung TY, Kim IY, et al. Polyion complex micelles composed of all-trans retinoic acid and poly(ethylene glycol)-grafted chitosan. J. Pharm. Sci. 2006; 95: 2348-60.

Krupitza G, Hulla W, Harant H, Dittrich E, Kallay E, Huber H. Retinoic acid induced death of ovarian carcinoma cells correlates with c-myc stimulation. Int. J. Cancer 1995; 61: 649-59.

Lehman PA, Slattery JT, Franz TJ. Percutaneous absorption of retinoids: Influence of vehicle, light exposure, and dose. J Invest Dermatol. 1988; 91: 56-61.

Lu T, Lin WJ, Izumi K, et al. Targeting androgen receptor to suppress macrophage?induced EMT and benign prostatic hyper­plasia (BPH) development. Mol Endocrinol. 2012; 26: 1707?15.

Norden AD, Wen PY. Glioma therapy in adults. Neurologist 2006; 12: 279-92.

Panman L, Zeller R. Patterning the limb before and after SHH signalling. J Anat. 2003; 202: 3?12.

Ruat M, Angot E, Traiffort E. Shh signal and its functional roles in normal and diseased brain. Med Sci (Paris). 2011; 27: 979?85.

Sandhu GS, Nepple KG, Tanagho YS, Andriole GL: Prostate cancer chemoprevention. Semin Oncol. 2013; 40: 276?85.

Snyder A, Tepper JE, Slovin SF. Perspectives on immuno­therapy in prostate cancer and solid tumors: Where is the future? Semin Oncol. 2013; 40: 347?60.

Stummer W, Kamp MA. The importance of surgical resection in malignant glioma. Curr Opin Neurol. 2009; 22: 645-49.

Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003; 3: 768?80.

Szuts EZ, Harosi FI. Solubility of retinoids in water. Arch Biochem Biophys. 1991; 287: 297-304.

Tanaka S, Louis DN, Curry WT, Batchelor TT, Dietrich J. Diagnostic and therapeutic avenues for glioblastoma: No longer a dead end? Nat Rev Clin Oncol. 2013; 10: 14-26.

Vaillant C, Monard D: SHH pathway and cerebellar devel­opment. Cerebellum 2009; 8: 291?301.

Wu Q, Hou X, Xia J, et al. Emerging roles of PDGF?D in EMT progression during tumorigenesis. Cancer Treat Rev. 2013; 9: 640?46.

How to Cite
Zhong, J., and J.-Q. Hou. “A Novel Retinoic Acid Chalcone Reverses Epithelial-Mesenchymal Transition in Prostate Cancer Cells”. Bangladesh Journal of Pharmacology, Vol. 10, no. 2, Apr. 2015, pp. 288-93, doi:10.3329/bjp.v10i2.22602.
Research Articles